Literature DB >> 29955580

Estimate risk difference and number needed to treat in survival analysis.

Zhongheng Zhang1, Federico Ambrogi2, Alex F Bokov3, Hongqiu Gu4,5, Edwin de Beurs6, Khaled Eskaf7.   

Abstract

The hazard ratio (HR) is a measure of instantaneous relative risk of an increase in one unit of the covariate of interest, which is widely reported in clinical researches involving time-to-event data. However, the measure fails to capture absolute risk reduction. Other measures such as number needed to treat (NNT) and risk difference (RD) provide another perspective on the effectiveness of an intervention, and can facilitate clinical decision making. The article aims to provide a step-by-step tutorial on how to compute RD and NNT in survival analysis with R. For simplicity, only one measure (RD or NNT) needs to be illustrated, because the other measure is a reverse of the illustrated one (NNT=1/RD). An artificial dataset is composed by using the survsim package. RD and NNT are estimated with Austin method after fitting a Cox-proportional hazard regression model. The confidence intervals can be estimated using bootstrap method. Alternatively, if the standard errors (SEs) of the survival probabilities of the treated and control group are given, confidence intervals can be estimated using algebraic calculations. The pseudo-value model provides another method to estimate RD and NNT. Details of R code and its output are shown and explained in the main text.

Entities:  

Keywords:  Pseudo-value; number needed to treat (NNT); risk difference (RD); survival analysis

Year:  2018        PMID: 29955580      PMCID: PMC6015956          DOI: 10.21037/atm.2018.01.36

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  9 in total

Review 1.  Calculating the number needed to treat for trials where the outcome is time to an event.

Authors:  D G Altman; P K Andersen
Journal:  BMJ       Date:  1999-12-04

Review 2.  Time-dependent covariates in the Cox proportional-hazards regression model.

Authors:  L D Fisher; D Y Lin
Journal:  Annu Rev Public Health       Date:  1999       Impact factor: 21.981

3.  SAS and R functions to compute pseudo-values for censored data regression.

Authors:  John P Klein; Mette Gerster; Per Kragh Andersen; Sergey Tarima; Maja Pohar Perme
Journal:  Comput Methods Programs Biomed       Date:  2008-01-15       Impact factor: 5.428

Review 4.  Pseudo-observations in survival analysis.

Authors:  Per Kragh Andersen; Maja Pohar Perme
Journal:  Stat Methods Med Res       Date:  2009-08-04       Impact factor: 3.021

5.  Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomes.

Authors:  Peter C Austin
Journal:  J Clin Epidemiol       Date:  2009-07-12       Impact factor: 6.437

6.  The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariables.

Authors:  J E Herndon; F E Harrell
Journal:  Stat Med       Date:  1995-10-15       Impact factor: 2.373

Review 7.  Risk-difference curves can be used to communicate time-dependent effects of adjuvant therapies for early stage cancer.

Authors:  Michael Coory; Karen E Lamb; Michael Sorich
Journal:  J Clin Epidemiol       Date:  2014-04-29       Impact factor: 6.437

8.  The hazards of hazard ratios.

Authors:  Miguel A Hernán
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

9.  Model-based estimation of measures of association for time-to-event outcomes.

Authors:  Federico Ambrogi; Elia Biganzoli; Patrizia Boracchi
Journal:  BMC Med Res Methodol       Date:  2014-08-09       Impact factor: 4.615

  9 in total
  5 in total

1.  Young-onset colorectal cancer risk among individuals with iron-deficiency anaemia and haematochezia.

Authors:  Joshua Demb; Lin Liu; Caitlin C Murphy; Chyke A Doubeni; María Elena Martínez; Samir Gupta
Journal:  Gut       Date:  2020-12-18       Impact factor: 31.793

2.  Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study.

Authors:  Ching-Lung Cheung; Chor-Wing Sing; Wallis C Y Lau; Gloria H Y Li; Gregory Y H Lip; Kathryn C B Tan; Bernard M Y Cheung; Esther W Y Chan; Ian C K Wong
Journal:  Cardiovasc Diabetol       Date:  2021-03-25       Impact factor: 9.951

3.  Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine.

Authors:  Nazmul Islam; Natalie E Sheils; Megan S Jarvis; Kenneth Cohen
Journal:  Nat Commun       Date:  2022-05-02       Impact factor: 17.694

4.  Multifaceted Intervention to Improve P2Y12 Inhibitor Adherence After Percutaneous Coronary Intervention: A Stepped Wedge Trial.

Authors:  P Michael Ho; Colin I O'Donnell; Marina McCreight; Anthony A Bavry; Hayden B Bosworth; Saket Girotra; P Michael Grossman; Christian Helfrich; Faisal Latif; David Lu; Michael Matheny; Kreton Mavromatis; Jose Ortiz; Amitabh Parashar; Devona M Ratliff; Gary K Grunwald; Michael Gillette; Hani Jneid
Journal:  J Am Heart Assoc       Date:  2022-06-29       Impact factor: 6.106

5.  A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society.

Authors:  Ji-Bin Li; Zhuo-Chen Lin; Martin C S Wong; Harry H X Wang; Mengmeng Li; Su Li
Journal:  BMC Med       Date:  2022-09-26       Impact factor: 11.150

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.